证券代码： 000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 编号：2025-001 | | □特定对象调研 □ 分析师会议 | | --- | --- | | □ 投资者关系活 | 媒体采访 √ 业绩说明会 | | □ 动类别 | 新闻发布会 □ 路演活动 | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 投资者网上提问 | | 时间 | 2025 年 5 月 13 日 (周二) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待 | 1、董事长吴海明 2、董事会秘书兼财务总监张誉锋 | | 人员姓名 | | | | 3、独立董事汪宏伟 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、您好，贵司 2024 年医药工业收入 6.72 亿元，其中制 | | | 剂和原料药毛利率分别为 61.25%和 20.24 ...

债券代码：123194 债券简称：百洋转债 股票代码：301015 股票简称：百洋医药 青岛百洋医药股份有限公司 投资者关系活动记录表 编号：IR2025-001 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | | --- | --- | --- | | | □媒体采访  业绩说明会 | | | | □新闻发布会 | □路演活动 | | | □现场参观 □其他 | | | 参与单位名称及人员姓名 | 参与公司 2025 年青岛辖区上市公司投资者网上集体接待日暨 | | | | 年度业绩说明会活动的投资者 2024 | | | 时间 | 2025 年 5 月 12 日 15:00-17:00 | | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 上市公司接待人员姓名 | 董事长、总经理：付钢 | | | | 财务总监、董事会秘书：李震 | | | | 独立董事：郝先经 | | | | 公司对投资者在本次活动中提出的问题进行了回复： 1、付总，贵公司一季报净利润下滑的情况下，如何保障二 | | | | 季度利润的稳定及增长？ | | | | 尊 ...

《2024年度环境、社会和公司治理(ESG)报告》封面 中国医药秉持"人才为本，质量为核"的核心理念，积极履行人文关怀，帮扶困难员工。公司不断完善质量管理体系，强化全员质量意识，中国医药及下属单 位中21家公司通过29项ISO9001、ISO13485质量管理体系认证，以严苛标准铸就品质标杆，持续以优质服务提升客户满意度。在供应链管理层面，中国医药 依托"客商云"及商贸ERP系统，搭建供应商管理数字化平台，以数字技术赋能管理升级，持续完善供应商管理与沟通机制，推动供应链绿色转型，携手供应 商共建阳光、诚信、可持续的供应生态。此外，中国医药投身公益事业，助力乡村振兴，立足专业优势，优选中药材产品，整合地方特色食品、农副产品以 在全球可持续发展浪潮下，中国医药（600056）健康产业股份有限公司(600056.SH)(以下简称"中国医药")始终秉持"责任治理"与"责任发展"理念，将环境、 社会和公司治理(ESG)融入战略核心。2025年4月26日，公司发布《2024年度环境、社会和公司治理(ESG)报告》(以下简称"本报告")，系统披露了其在绿色 转型、社会责任、治理创新等方面的实践与成效。中国医药立足"科、工、 ...

医药生物行业 2024&2025Q1 财报总结：创新与出海驱 动结构性机会 20250511 摘要 • 医药行业估值处于近十年低位，申万医药行业市盈率约为 26 倍，远低于 近十年中枢估值 36 倍和最高估值 73 倍，仅为申万行业平均估值的 76%，具备估值修复空间，但需关注集采政策和创新药入院进度。 • 2024 年医药生物行业营收同比下降 1.4%，归母净利润同比下降 14.4%。但 2025 年 Q1 数据显示，行业营收环比提升 1.78%，归母净利 润环比大幅提升 1,379%，显示出复苏迹象，其中医疗服务和原料药板块 表现突出。 • 化学制剂板块表现最佳，2024 年收入同比增长 2.1%，规模同比增长 35%，归母净利润同比唯一实现正增长，受益于创新政策利好和集采政策 缓和预期。中药板块跌幅最大，但净利率有所恢复，在特定疾病领域仍具 优势。 • 中国制药企业全球化加速，2024 年跨境许可交易总额超 423 亿美元， 2025 年 Q1 中国医药交易金额占全球一半以上，同比增长超 200%，成 为全球医药交易的重要引擎，尤其在肥胖、中枢神经系统等领域表现突出。 Q&A 2025 年医药生物行业的 ...

Group 1 - The core viewpoint of the articles indicates that Luyuan Pharmaceutical's revenue has surpassed 20 billion yuan for the first time, reaching 20.471 billion yuan in 2024, with a year-on-year growth of 3.15%, while the net profit attributable to shareholders has declined by 4.92% to 346 million yuan, marking the first negative growth in recent years [2] - From the first quarter of 2024, Luyuan Pharmaceutical's quarterly profits have consistently declined, dropping from a growth of 4.9% to a decline of 14.86% in the first quarter of 2025 [2] - The pharmaceutical wholesale business accounted for 90.8% of total revenue in 2024, but its growth rate was only 1.85%, which negatively impacted overall performance; in contrast, the pharmaceutical retail and industrial businesses maintained double-digit growth rates of 14.46% and 25.16%, respectively, but their revenue contributions were insufficient to reverse the downturn [2] Group 2 - Luyuan Pharmaceutical's business heavily relies on a pure sales model, directly supplying to public hospitals at the secondary level and above, which, while securing quality clients, has led to a continuous rise in accounts receivable [2] - As of the end of 2024, the accounts receivable value was 5.902 billion yuan, accounting for 46.7% of total assets, and by the end of the first quarter of 2025, it further increased to 6.258 billion yuan, approaching 50% [2] - The high accounts receivable directly affects cash flow, with Luyuan Pharmaceutical's net cash flow from operating activities dropping by 55.89% to 577 million yuan in 2024, and a net outflow of 81 million yuan in the first quarter of 2025, although this was a narrowing year-on-year [2] Group 3 - In recent years, Luyuan Pharmaceutical has implemented a "going out of Fujian" strategy through acquisitions, achieving over 96% coverage of secondary hospitals in Sichuan, Jiangxi, and Hainan provinces; however, the effectiveness of regional expansion has varied significantly [3] - In 2024, the revenue contribution from Fujian province was 70.47%, with a growth rate of only 2.19%, nearly stagnant; Sichuan province contributed 16.45% with a year-on-year growth of 10.24%, while Jiangxi province accounted for 9.78% with a decline of 0.81% [3] - Future growth for Luyuan Pharmaceutical will likely depend on seeking development opportunities outside of its home province [3]

Core Viewpoint - The article emphasizes the importance of enhancing the quality of listed companies in Shanghai, focusing on cultivating high-performing, innovative, and well-governed firms that are recognized in the market [1][2]. Group 1: Shanghai State-owned Enterprises Performance - As of the end of 2024, the total market value of 94 state-owned listed companies in Shanghai reached 2.78 trillion yuan, an increase of 617.74 billion yuan, or 28.52% from the beginning of the year [1]. - The Shanghai Municipal State-owned Assets Supervision and Administration Commission aims to complete high-quality reforms and enhance the market value performance of state-owned listed companies [2]. Group 2: Company Highlights Shanghai Port Group - In 2024, Shanghai Port Group achieved a container throughput of 51.506 million TEUs, a year-on-year increase of 4.8%, maintaining its position as the world's largest port for 15 consecutive years [3]. - The company's net profit attributable to shareholders reached 14.95 billion yuan, a growth of 13.3% year-on-year [3]. Huayi Group - Huayi Group reported a revenue of 44.6 billion yuan in 2024, a 9.3% increase year-on-year, with a net profit of 0.91 billion yuan, up 5.8% [5]. - The company applied for 151 patents, receiving 134 authorizations, and is focusing on strategic emerging sectors [5][6]. Shanghai Pharmaceuticals - Shanghai Pharmaceuticals achieved a revenue of 275.251 billion yuan, a 5.75% increase, and a net profit of 4.553 billion yuan, up 20.82% [6][7]. - The company is optimizing its R&D system and has established a new innovation center to enhance its open innovation ecosystem [7]. Pudong Development Bank - Pudong Development Bank reported a net profit of 45.3 billion yuan in 2024, a 23.31% increase, marking the highest growth in nearly 12 years [9]. - The bank is focusing on technology finance and has developed a comprehensive cross-border financial service system [10][11]. China Pacific Insurance - China Pacific Insurance reported a revenue of 404.089 billion yuan, a 24.7% increase, and a net profit of 44.96 billion yuan, up 64.9% [11][12]. - The company is enhancing its green insurance offerings and has provided coverage exceeding 147 trillion yuan in green insurance [13]. Data Harbor - Data Harbor achieved a revenue of approximately 1.721 billion yuan, an 11.57% increase, and a net profit of approximately 132 million yuan, up 7.49% [14][15]. - The company is focusing on IDC services and has been recognized as a top service provider in the industry [14].

Group 1: Core Insights - The Shanghai Municipal State-owned Assets Supervision and Administration Commission and the Shanghai Stock Exchange held a performance briefing to enhance the quality of state-owned listed companies and strengthen investor relations [1][2] - The total market value of 94 state-owned listed companies in Shanghai reached 2.78 trillion yuan, an increase of 617.77 billion yuan or 28.52% from the beginning of the year [1] Group 2: Company Highlights - Shanghai Port Group achieved a container throughput of 51.51 million TEUs, a year-on-year increase of 4.8%, maintaining its position as the world's largest port for 15 consecutive years [3] - Shanghai Port Group's net profit attributable to shareholders reached 14.95 billion yuan, a 13.3% increase year-on-year [3] - Huayi Group reported a revenue of 44.6 billion yuan, a 9.3% increase, and a net profit of 910 million yuan, up 5.8% [5][6] - Shanghai Pharmaceutical achieved a revenue of 275.25 billion yuan, a 5.75% increase, and a net profit of 4.55 billion yuan, a 20.82% increase [8][9] - Pudong Development Bank's net profit reached 45.3 billion yuan, a 23.31% increase, marking the highest growth in nearly 12 years [10][11] - China Pacific Insurance Group reported a revenue of 404.09 billion yuan, a 24.7% increase, and a net profit of 44.96 billion yuan, a 64.9% increase [13][14] - DataPort achieved a revenue of approximately 1.72 billion yuan, an 11.57% increase, and a net profit of approximately 132 million yuan, a 7.49% increase [15][16] Group 3: Strategic Initiatives - Shanghai Port Group is focusing on digital, intelligent, and green transformation to enhance its core business and sustainable development capabilities [3][4] - Huayi Group is advancing major technological projects and has filed 151 patents, with 134 granted [6][7] - Shanghai Pharmaceutical is optimizing its R&D system and has established a new innovation center to accelerate the development of a collaborative ecosystem [8][9] - Pudong Development Bank is implementing a digital finance strategy and enhancing its service efficiency through various digital platforms [10][11] - China Pacific Insurance is expanding its green insurance offerings and enhancing its technology-driven services [13][14] - DataPort is deepening its IDC service capabilities and has been recognized as a top service provider in the industry [15][16]

上海市国资委以提高上市公司发展质量为抓手，全力培育和打造一批经营业绩佳、创新能力强、治理体系优、市场认可度高的一流上市公司。其中，上港集 团母港集装箱吞吐量连续15年保持世界首位，上海港成为全球首个年集装箱吞吐量超过5000万标准箱的世界大港。2024年，上港集团港口能力建设扎实推 进，罗泾港区改造一期工程实现开港运营，罗泾港区改造二期工程获得核准批复，小洋山北侧工程建设按节点目标扎实推进。 5月9日，上海市国资委联合上海证券交易所举办上海国有控股上市公司2024年度集体业绩说明会，旨在推动上海国有控股上市公司进一步强化投资者关系管 理、增进市场认同，提升内在价值。上港集团（600018）、华谊集团（600623）、上海医药（601607）、浦发银行、中国太保（601601）、数据港 （603881）等6家在上交所挂牌的上海国有控股上市公司参加本次业绩说明会。 上港集团副总裁、董事会秘书、总法律顾问丁向明表示："进入4月份，尽管公司在美国的航线业务量出现了一定波动，但从4月份集装箱吞吐量来看，同比 仍有所增长。"他同时透露，公司将加强动态数据趋势监控，积极推进业务模式创新，深化在长三角港口群的协同效应，通过创 ...

为贯彻落实中国证监会《上市公司监管指引第10号——市值管理》、上海市国资委《关于加强我市国有控股上市公司市值管理工作的若干意见》等文件精 神，推动我市国有控股上市公司在做强做优做大、提升内在价值的同时，进一步强化投资者关系管理、提高信息透明度、增进市场认同，上海市国资委联 合上海证券交易所，于2025年5月9日下午共同举办上海国有控股上市公司2024年度集体业绩说明会。上海市国资委副主任林益彬出席活动。 上港集团、华谊集团、上海医药、浦发银行、中国太保、数据港等6家在上交所挂牌的上海国有控股上市公司参加本次业绩说明会，同时邀请部分投资 者、分析师、媒体现场参会。6家上市公司的董事长、财务负责人、董事会秘书、独立董事等通过"现场交流+线上互动"方式，解析公司业绩，全方位展示 6家上市公司在经营发展、产业布局、技术创新、ESG建设、投资者回报等方面的成效与未来规划，并与投资者、分析师、媒体等展开深入交流，回答投 资者提问，倾听投资者建议。 上海市国资委始终聚焦服务上海"五个中心"建设重要使命，以提高上市公司发展质量为抓手，全力培育和打造一批经营业绩佳、创新能力强、治理体系 优、市场认可度高的一流上市公司。根据6家 ...

证券代码：600713 证券简称：南京医药 编号：ls2025-062 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于调整 2025 年限制性股票激励计划相关事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、 《南京医药 股份有限公司 2025 年限制性股票激励计划（草案）》（以下简称"《激励计划》"） 的相关规定以及公司 2025 年第一次临时股东大会决议的授权，南京医药股份有限 公司（以下简称"公司"）于 2025 年 5 月 9 日召开第九届董事会第十次会议和第九 届监事会第十次会议，审议通过了《关于调整 2025 年限制性股票激励计划相关事 项的议案》，现将有关调整事项公告如下： 一、公司 2025 年限制性股票激励计划（以下简称"本次激励计划"）已履行 的决策程序和信息披露情况 《激励计划》及其摘要、《南京医药股份有限公司 2025 年限制性股票激励计划考 核管理办法》 《南京医药股份有限公司 2025 （以下简称"《激 ...